NT-I7 + pembrolizumab showed significant clinical activity in checkpoint inhibitor–naïve, relapsed/refractory microsatellite stable colorectal cancer and pancreatic cancer without liver metastasis. @ANaingMD@MDAndersonNews#crcsm#pancsmow.ly/Xs7x50LX11U
NeoImmuneTech is excited to be participating in this year’s @BIOConvention from June 8-12. We look forward to connecting with fellow biotech innovators in spaces like #immunooncology and #infectiousdisease during this year’s new digital meeting. #BIODigital